Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine for Neuromuscular Block Reversal in ENT Surgery
NCT02698969Phase 4Unknown
- Sponsor
- Università degli Studi di Firenze
- Start
- Nov 2014
- Primary completion
- Feb 2017
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Sugammadex in Postoperative residual curarization (PORC) (2 arms), sponsored by Università degli Studi di Firenze. Primary endpoint: Post-operative Residual Curarization assessed by Diaphragm Ultrasonography. Status: unknown.
02
Drugs
Sugammadex
03
Conditions
Postoperative residual curarization (PORC)
Beyond the preview
Go deeper on NCT02698969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02698969.